Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 460 participants.

Also called NCT01612260

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 460 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01612260
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01612260. Randomized; quadruple masking; primary purpose treatment. Start 2012-09 (registry gives no type); primary completion 2013-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat
Condition
Heart Failure
Condition
Ventricular Premature Complex
Intervention (Drug)
Shensong Yangxin capsule
Intervention (Drug)
placebo Capsule
Lead sponsor
Cong-xin Huang (class: other)
Collaborator
Chinese Academy of Medical Sciences, Fuwai Hospital (class: other)
Collaborator
Fudan University (class: other)
Collaborator
Shanghai Changzheng Hospital (class: other)
Collaborator
Nanjing Medical University (class: other)
Collaborator
Third Military Medical University (class: other)

Record details

Record id
cardio:ct-nct01612260
Content hash
f266079cde44383001708a0b6c64a339b932748ddcf5d385640c1e42097342fa